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Bone marrow transplantation and organ transplantation studies suggest 
that bone marrow cells can differentiate into a variety of non-hematological 
tissues, including renal cells. The results of a number of experimental 
animal studies also showed that cell therapy (bone marrow cells [BMCs], 
hematopoietic stem cells [HSCs], mesenchymal stem cells [MSCs]) might 
have the potential to rescue animals from organ injuries. However, when 
BMCs or HSCs were injected into rodents subjected to ischemic or toxin-
induced acute tubular necrosis (ATN), the results with regard to whether 
they could rescue rodents from ATN were inconsistent. The reasons for the 
conflicting results of BMC or HSC therapy in ATN are unknown, but may be 
due to the different types of cells injected, number of cells injected, route 
of injection, or injury model of acute renal failure. It is known that MSCs 
can contribute to renal tubular regeneration after ATN, although the exact 
mechanism, either transdifferentiation or effects of paracrine/cytokines, is 
uncertain. In the future, the most pertinent issue is to determine how MSCs 
protect the renal tubule from injury, and then to imitate this protective or 
reparative effect pharmacologically. [Tzu Chi Med J 2007;19(3):115–126]
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1. Introduction
Acute renal failure (ARF) is defined as a rapid decline 
in glomerular filtration rate (GFR) occurring within 
hours or days, resulting in the failure of the kidney to 
excrete nitrogen waste products, and failure to main-
tain extracellular fluid volume, electrolyte and acid-
base homeostasis [1–4]. Definitions of ARF range from 
a slight rise in serum creatinine concentration (e.g. 
of 0.5 mg/dL) to severe ARF status (i.e. that requiring 
dialysis). Although there is no universal laboratory 
definition, it is reasonable to define ARF as a rise in 
serum creatinine levels for 2 weeks or less of 0.5 mg/dL 
(44.2 μmol/L) if the baseline is less than 2.5 mg/dL, 
or a rise in serum creatinine levels by more than 20% 
if the baseline is more than 2.5 mg/dL [4].
ARF may occur in three clinical settings: (1) as a 
result of severe volume depletion and hypotension 
without compromising the integrity of renal paren-
chyma (prerenal ARF); (2) obstruction to the urinary 
tract (postrenal ARF); and (3) diseases that directly 
affect renal parenchyma (intrinsic renal ARF). Prerenal 
ARF can be corrected if the extrarenal factors caus-
ing the renal hypoperfusion are reversed. In addi-
tion, an obstructive cause of ARF must be excluded 
because prompt intervention can lead to improve-
ment or complete recovery of renal function. Acute 
tubular necrosis (ATN), resulting from prolonged 
renal hypoperfusion and renal ischemia or nephro-
toxic substances, is a pathological diagnosis. Patho-
physiologically, ATN is associated with tubular cell 
death and shedding into the tubular lumen, result-
ing in tubular blockage, further reducing glomerular 
filtration. Despite major advances in intensive care, 
renal replacement therapy, and exploration of cellular 
and molecular pathogenesis of ARF, no specific ther-
apy is currently available. Consequently, the overall 
mortality rate of patients with ARF is still high, about 
50% in a recent series [3,5,6], and has changed little 
during the past 30 years. Therefore, a more powerful 
therapeutic intervention for ATN to decrease mortal-
ity rate is imperative. Recently, a number of studies 
have provided evidence that bone marrow stem cells 
(BMSCs) may have a great potential to rescue people 
from organ injury. Here, we introduce the present 
studies on BMSCs in patients with renal diseases and 
discuss the future direction for applying BMSCs to 
renal regeneration.
2. Stem cells
2.1.  Totipotent, pluripotent and 
multipotent
A stem cell is defined as a cell from the embryo, 
fetus, or adult that is capable of self-renewal over 
long periods and differentiation to one or more types 
of specialized cells under certain conditions [7].
Competent levels of stem cells can be classified as 
either totipotent (able to contribute to all three embry-
onic germ layers as well as extraembryonic tissues), 
pluripotent (giving rise to all three germ layers of the 
embryo), or multipotent (with the potential to differ-
entiate into multiple cell types, but not derivatives of 
all three germ layers).
2.2. Embryonic stem cells
Embryonic stem (ES) cells are derived from the inner 
cell masses of the blastocysts and are pluripotent [8]. 
The pluripotent character of ES cells may provide ther-
apeutic potential for many disorders. However, there 
are still several issues remaining unresolved about 
using ES cells from human embryos and applying 
them to clinical applications, including uncontrolled 
growth of inappropriate tissue types, rejection com-
plications, and ethical issues.
2.3. Adult stem cells
In adult organisms, each tissue and organ are believed 
to contain a small subpopulation of cells, i.e. tissue-
specific stem cells that remain committed to support 
their own family of descendants. Hemato poietic stem 
cells (HSCs) are the best characterized; this knowledge 
has allowed therapeutic grafting to make a tremen-
dous impact on hematological malignancy and offers 
great promise for hemoglobinopathies and other 
genetic diseases [9]. A recent study showed in vitro 
expanded renal-derived CD133+ cells homed into the 
injured kidney and integrated into tubules. However, 
it cannot be excluded that these CD133+ cells might 
have been contaminated from the blood of renal micro-
circulation because these cells were directly obtained 
from the cortex without pre-infusion with isotonic 
sodium chloride solution [10]. Therefore, do renal 
stem cells exist in the adult kidneys? Most researchers 
agree that the kidney should contain organ-specific 
stem cells like other adult organs, but no researchers 
claim they can recognize functional renal stem cells 
either by location or by characteristic morphology or 
surface mole cule expression [11,12].
3.  BMSCs and their therapeutic 
potential
3.1. Plasticity of BMSCs
BMSCs are a many-faceted population and have been 
classified as HSCs, marrow stromal cells (or MSCs), 
multipotent adult progenitor cells (MAPCs), and side 
population (SP) cells [13]. Bone marrow transplanta-
tion (BMT) is an existing mode of stem cell therapy 
for patients with blood disorders such as leukemia. 
More than four decades of accomplished in vivo BMT 
studies have clarified the activities of a rare BMSC 
that is both self-renewing and multipotent in its ability 
to give rise to all blood cell types and provide recipi-
ents with long-term repopulating cells [9]. Traditionally, 
adult stem cells were believed to be lineage-restricted 
and organ-specific. Therefore, it was not thought pos-
sible that stem cells derived from bone marrow could 
not only rescue patients with hematological disorders 
but also extricate non-hematopoietic tissues from 
organ damage, i.e. the existence of stem cell plasti-
city had not been recognized. The first significant 
report alerting to the possibility of stem cell plasticity 
was published by Ferrari et al [14] who transplanted 
bone marrow cells (BMCs) into recipient mice and 
subsequently injured the muscles of these recipient 
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animals. Surprisingly, donor cell nuclei were found 
incorporated into the regenerated skeletal muscle at 
a frequency of approximately 0.01%. Now, a growing 
number of studies based on simple BMT protocols 
have claimed that adult BMSCs can differentiate into 
a variety of non-hematological tissues in rodents, such 
as skeletal muscle [14], astrocytes [15], osteoblasts 
[16], endothelial cells [17], cardiomyocytes [18], neu-
ronal cells [19,20], hepatocytes [21], epidermal cells 
[22], pneumocytes [22,23], renal tubular epithelium 
and podocytes [24], and gut cells [22,25]. Likewise, in 
humans, bone marrow can apparently differentiate 
into hepatocytes [26,27], renal tubular cells [24], epi-
thelium of the skin [27], skeletal muscle [28], cardio-
myocytes [29], epithelia of gastrointestinal tract [27,
30], respiratory tract [31], and neurons [32,33].
3.2.  Cell fusion between BMCs and 
differentiated cells in engrafted 
organs
Although some researchers have questioned stem 
cell plasticity and showed this is really the result of 
the fusion of BMCs with the differentiated cells in 
the engrafted organ including hepatocytes [34–36], 
Purkinje cells [36,37], cardiomyocytes [36] and skel-
etal muscle cells [38,39], a number of studies have 
demonstrated that cell fusion is not a major player in 
the transdifferentiation of BMCs into various specific 
cell types (reviewed in [40,41]).
4.  Therapeutic potential of BMCs for 
extrarenal diseases
Through the establishment of bone marrow chimer-
ism, a few successful cases of HSC transplantation 
in utero have rescued patients with severe com-
bined immunodeficiency disease, β-thalassemia, and 
Bloom’s syndrome [42,43]. Moreover, the results of a 
series of studies have shown the possibility that bone 
marrow grafting could act as cell therapy for non-
hematological diseases, such as osteogenesis imper-
fecta [44–46]. Horwitz et al [44] showed that BMT 
improved certain parameters of patients with osteo-
genesis imperfecta, and stromal cell cultures from 
bio psies of recipient bones indicated that donor-
derived cells were present. A subsequent study 
showed that further administration of mesenchymal 
cells cultured from the same donor gave some fur-
ther improvement of clinical parameters due to the 
formation of functional wild-type osteoblasts from 
the donor mesenchymal cells, although gene-marked 
cells when detectable were < 1% of cells in bone cul-
tures [46]. Recently, experimental and early clinical 
studies have supported the concept that autologous 
bone marrow infusions were beneficial in chronic 
limb ischemia [47], ischemic heart disease [48], and 
myocardial infarction [49,50] in humans, although 
the benefits appeared to be related to preserving or 
re-establishing microvessels and limiting the extent 
and severity of the damage [51].
4.1. Engraftment of BMCs as renal cells
Table 1 [22,24,52–78] shows the potential of BMCs to 
transdifferentiate into renal cells according to the study 
results of cross-sex BMT and kidney transplantation.
4.2.  Engraftment of BMCs as renal 
vessels and interstitium
Considering the renal vessels and interstitium, the 
results of early studies of renal vascular engraftment 
by Williams et al [52,53] and Sinclair [54] showed, 
based on cross-sex renal transplant studies, that 
repopu lated endothelium of vessels may be derived 
from circulating cells when chronic rejection of allo-
grafts occurred. Williams et al reported that 10% of 
the endothelium in allografts of the kidney and aorta 
could be from the host marrow when chronic rejec-
tion of allografts occurred, and engraftment was less 
when rejection was attenuated by immunosuppres-
sion [52,53]. Sinclair [54] counted Barr bodies in 40 
male patients with female renal transplants and showed 
donor endothelium persisted in 37 of 40 cases, but not 
in three patients with grafts that were very poorly func-
tioning and severely damaged. How ever, Andersen 
et al [55] examined kidney specimens from 40 sex-
mismatched transplant patients clinically suggested of 
developing acute rejection, and reported that there 
was no evidence of revascularization by recipient 
endothelial cells; furthermore, tubular and glomeru-
lar cells remained of donor origin in the transplanted 
kidneys with acute rejection, even 10 months after 
transplantation. Recently, the results of two studies 
showed that vascular endothelium [58,61] and tubu-
lointerstitial cells [58] were of host origin when allo-
grafts of human kidneys show chronic rejection. The
percentage of engraftment of vascular endothelium of 
host origin was more than 33% in the majority of 
patients (86%) with vascular rejection [58,61]. Simi-
larly, the percentage of vascular endothelium of host 
origin was 34–76% in allografts with vascular rejec-
tion, and the percentage of interstitial cells of host 
origin was 30–77% in allografts with interstitial rejec-
tion [58]. These results suggest circulating mesen-
chymal precursors reside within the bone marrow 
and migrate to vessels or interstitial areas when allo-
graft rejection occurs. However, the results from a 
study by Iwano et al showed that interstitial kidney 
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fibroblasts were derived not only from bone marrow 
but also from local tubular epithelium [64].
4.3.  Engraftment of BMCs as glomerular 
mesangial cells and podocytes
Turning to glomerular mesangial cells and podocytes, 
Poulsom et al and Sugimoto et al demonstrated that 
BMCs contributed to podocyte regeneration and ame-
lio ration of renal disease in a mouse model of Alport 
syndrome [24,77,79]. Regarding mesangial cells, 
Cornacchia et al demonstrated that mesangial cell pro-
genitors may carry a disease genotype and that the 
phenotype can be transmitted after BMT [57]. Several 
studies also showed that BMCs differentiated into 
glomerular mesangial cells in rodents with and without 
glomerular injury [59,60,63,68,78]. More over, Masuya 
et al reported that transplantation of a single HSC could 
generate numerous glomerular mesangial cells [67].
4.4.  Engraftment of BMCs as renal tubular 
epithelium
Considering renal tubular epithelium, Poulsom et al 
demonstrated that BMSCs contributed to both normal 
turnover of renal epithelium in mice and the level 
of engraftment in renal tubular cells was 3–8%, and 
regeneration after damage in humans where the level 
of engraftment in renal tubular cells was 1.8–20% 
[24]. Animal studies from our group and other groups 
also showed that BMCs contributed to renal regener-
ation after ATN [70,71]. However, not all reports were 
compatible with these studies. Krause et al showed 
that no donor-derived renal tubule epithelial cells were 
seen in any of the five mice transplanted with a single 
highly selected HSC, perhaps ineffective due to the 
use of a sorted HSC rather than the whole bone mar-
row [22]. However, it is unknown whether epithelial 
chimerism is an incidental by-product of cross-gender 
BMT and renal allografts without biological meaning 
or whether alternatively the process plays a role in kid-
ney repair. For example, Gupta et al reported that 1% 
of tubules contained male epithelial cells in two male 
patients with female kidney allografts and ATN, how-
ever, no male epithelial cells were noted in two cases 
without ATN, suggesting that recipient-derived cells 
do not routinely repopulate the transplanted kidney 
[62,80]. These findings contrast with recent observa-
tions by Mengel et al who showed that chimeric tubu-
lar epithelial cells (2.4–6.6%) occurred regularly in 
allografts, and was not correlated with outcome [69]. 
The results of our recent study demonstrated that 
BMCs contributed to the renal tubular epithelial cell 
population and regenerated renal tubular epithelium 
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5.  Therapeutic potential of BMC 
therapy for ATN
Table 2 [66,73,81–88] shows the conflicting results 
of BMC therapy for acute renal injury. The reasons for 
the conflicting results of BMC therapy in acute renal 
injury are unknown, but may be due to the different 
types of injected cells, number of injected cells, route 
of injection, or injury model of ARF.
5.1. Whole BMC therapy for ATN
It is still conflicting whether whole BMCs can con-
tribute to tubular regeneration after ATN [66,85]. For 
example, Kale et al demonstrated that the engraft-
ment of renal tubular cells of the outer medulla from 
BMCs increased from 3.0 ± 0.1% to 20.9 ± 1.6% after 
ischemia–reperfusion (I/R) renal injury [66], sugges t-
ing a major contribution of BMCs to functional repair of 
the ischemically injured tubule. However, the results 
of another study showed that BMCs did not improve 
renal function after I/R renal injury, although a rise 
in engraftment of tubular epithelial cells, glomerular 
cells and interstitial cells was seen [85].
5.2. HSC therapy for ATN
With regard to HSC therapy for ATN, it is still uncertain. 
For example, Lin et al studied female non-transgenic 
mice subjected to 11 Gray γ-irradiation 2 hours before 
the left renal artery was clamped for 15 minutes, 
and 2000 RhloLin-Sca-1+ckit+ HSCs from male ROSA26 
mice were injected into the female mice within hours 
after the unilateral renal I/R injury [81]. Four weeks 
after I/R renal injury, HSC-derived tubular epithelium 
was seen only with ischemic damage, and the percent-
age of Y chromosome-positive cells in the regenerating 
renal proximal tubules was 8.3 ± 3.2%. However, Dekel 
et al showed that human BM CD34+ HSCs when injec-
ted into NOD/SCID mice subjected to I/R renal injury via 
renal pelvis could not improve renal function and these 
cells could not acquire a tubular phenotype [87].
5.3. MSC therapy for ATN
With regard to MSC therapy for ATN, it is established 
that MSCs can contribute to regeneration of renal 
tu bules after ATN, although the exact mechanism is 
controversial. There are at least two possible mecha-
nisms for MSCs to rescue ATN: transdifferentiation 
of MSCs into renal tubule cells and paracrine and/
or angiogenic effects of MSCs. However, it is not 
known which one is more important. For example, two 
studies demonstrated that MSCs, when injected into 
non-irradiated mice subjected to cisplatin-induced 
or glycerol-induced ATN, could rescue mice from 
acute tubular damage and differentiate into renal 
tubular epithelium [82,83]. However, the results 
of other studies showed that the administration of 
MSCs via carotid artery either immediately or 24 
hours after renal ischemia [73,84,86] or via either 
tail veins or left renal artery 1 day after anti-Thy1.1 
nephritis induction [88], significantly improved renal 
function through a change in the cytokine milieu or 
paracrine growth factor release, but not because of 
their transdifferentiation into renal tubular cells. The 
reason for the discrepant results of MSC transdiffer-
entiation into renal epithelial cells between these 
two kinds of studies is unclear.
In fact, MSCs not only release angiogenic (vascular 
endothelial growth factor) and anti-inflammatory 
cytokines (transforming growth factor β1), but MSCs 
also have strong immunosuppressive activity [89]. 
However, it is still conflicting if administration of 
MSCs to people subjected to ATN can develop a 
neo-expressing protein and may induce an immune 
response. For example, several studies demonstrated 
that MSCs had shown strong immunosuppressive 
activity [89], and modulated the immune response 
via modifying the cytokine response of dendritic cells 
and T cells, via interfering with the development of 
immunocompetent dendritic cells, and via favoring 
the development of regulatory T cells [90,91]. In con-
trast, one recent study showed that the administra-
tion of allogeneic donor MSCs primed naïve T cells 
and hastened rejection of the bone marrow, whereas 
recipient autologous MSCs promoted tolerance and 
acceptance of transplants [92].
6. Conclusion
Studies of tissue from recipients of BMT or organ 
allografts suggest that BMCs can differentiate into a 
variety of non-hematological tissues, including renal 
cells. However, it is uncertain whether BMCs or HSCs, 
when injected into rodents subjected to ischemic or 
toxin-induced ATN, could rescue rodents from ATN. 
The reasons for the conflicting results of BMC or HSC 
therapy in ATN are unknown, but may be dependent 
on the different types of injected cells, number of 
injected cells, route of injection, or injury model of 
ARF. MSCs could contribute to renal tubular regenera-
tion after ATN, although the exact mechanism, either 
transdifferentiation of MSCs or effects of paracrine/
cytokines, is uncertain. In the future, the most perti-
nent issue is to determine exactly how MSCs protect 
the renal tubule from injury, and then to imitate this 
protective or reparative effect pharmacologically. If the 
primary role of MSCs is to secrete a cytokine or growth 
factor in response to injury, then the cells themselves 





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































124 TZU CHI MED J  September 2007  Vol 19  No 3
might not be essential, and we should be able to rec-
ognize the factor or factors and either administer it 
directly or establish pharmacological policy to stimu-
late its production by endogenous cells.
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